河北医学2024,Vol.30Issue(10) :1739-1745.DOI:10.3969/j.issn.1006-6233.2024.10.029

布地奈德联合干扰素α2b雾化治疗在婴幼儿支气管肺炎治疗中的疗效与安全性评估

Evaluation of the Efficacy and Safety of Budesonide Combined with Interferon α2b Nebulization in the Treatment of Infantile Bronchopneumonia

袁斌 蔡金标 王娟 吕亚莉 李晓会
河北医学2024,Vol.30Issue(10) :1739-1745.DOI:10.3969/j.issn.1006-6233.2024.10.029

布地奈德联合干扰素α2b雾化治疗在婴幼儿支气管肺炎治疗中的疗效与安全性评估

Evaluation of the Efficacy and Safety of Budesonide Combined with Interferon α2b Nebulization in the Treatment of Infantile Bronchopneumonia

袁斌 1蔡金标 1王娟 1吕亚莉 1李晓会1
扫码查看

作者信息

  • 1. 皖北煤电集团总医院儿内科,安徽 皖北 234000
  • 折叠

摘要

目的:探究布地奈德联合干扰素 α2b 雾化治疗在婴幼儿支气管肺炎治疗中的疗效与安全性评估.方法:纳入我院在2021 年9 月至2023 年7 月收治的102 例支气管肺炎婴幼儿,按照随机数字表法将其分为常规组(给予常规对症治疗+布地奈德雾化吸入)与联合组(在常规组基础上联合干扰素α2b雾化吸入),各51 例.对比两组患儿临床疗效、症状(咳嗽、喘憋、哮鸣音、三凹征)好转时间、治疗前后血气指标[氧合指数、氧分压(PaO2)、二氧化碳分压(PaCO2)]、T 淋巴细胞指标[CD3+CD4+、CD3+CD8+、CD3-CD19+]变化,对比药物不良反应.结果:联合组总有效率(98.40%)高于常规组(86.27%)(P<0.05);联合组症状好转时间均短于常规组(P<0.05);治疗前,2 组血清指标差异无统计学意义(P>0.05),治疗后,2 组患儿氧合指数与PaO2 均升高(P<0.05),PaCO2 下降(P<0.05),联合组治疗前后差值高于常规组(P<0.05);治疗前,2 组 T 淋巴细胞指标差异无统计学意义(P>0.05),治疗后,2组患儿CD3+CD4+、CD3+CD8+均上升(P<0.05),CD3-CD19+下降(P<0.05),联合组治疗前后差值高于常规组(P<0.05);治疗前,2 组外周血炎症指标差异无统计学意义(P>0.05),治疗后,2 组患儿外周血炎症指标(IL-6、TNF-α、CRP)均下降(P<0.05),联合组治疗前后差值高于常规组(P<0.05);联合组药物不良反应合计发生率(7.84%)与常规组(5.88%)差异无统计学意义(P>0.05).结论:布地奈德联合干扰素α2b雾化吸入治疗利于改善支气管肺炎婴幼儿临床症状、肺功能及免疫炎症反应,提升疗效,安全性高,值得应用.

Abstract

Objective:To evaluate the efficacy and safety of budesonide combined with interferon α2b nebulization in the treatment of infantile bronchopneumonia.Methods:A total of 102 infants and young chil-dren with bronchopneumonia admitted to our hospital from 2021.09 to 2023.07 were enrolled.According to the random number table method,they were divided into the conventional group(conventional symptomatic treatment+budesonide atomization inhalation)and combined group(combined with interferon α2b atomiza-tion inhalation on the basis of the conventional group),with 51 cases in each group.The clinical efficacy,im-provement time of symptoms(cough,wheezing,wheezing rale,three concave signs),blood gas indexes[oxy-genation index,partial pressure of oxygen(PaO2),partial pressure of carbon dioxide(PaCO2)],T lympho-cyte indicators(CD3+CD4+,CD3+CD8+,CD3-CD19+)and peripheral blood inflammation indexes[Interleu-kin-6(IL-6),tumor necrosis factor α(TNF-α),C-reactive protein(CRP)]before and after treatment were compared between the two groups,and the adverse drug reactions were compared.Results:The total ef-fective rate of the combined group(98.40%)was higher than that of the conventional group(86.27%)((P<0.05).The improvement time of symptoms in the combined group was shorter than that in the conventional group(P<0.05).Before treatment,there were no statistical differences in serum indexes between groups(P>0.05).After treatment,the oxygenation index and PaO2 in the two groups were increased(P<0.05)while the PaCO2 was decreased(P<0.05),and the differences before and after treatment in the combined group were higher(P<0.05).No statistical differences were shown in T lymphocyte indexes between groups before treatment(P>0.05).After treatment,CD3+CD4+and CD3+CD8+in both groups of children were risen(P<0.05)while CD3-CD19++was declined(P<0.05),and the differences before and after treatment were higher in the combined group than those in the conventional group(P<0.05).Before treatment,there were no statistical differences in peripheral blood inflammation indexes between groups(P>0.05).After treatment,the peripheral blood inflammatory indexes(IL-6,TNF-α,CRP)in the two groups were significantly de-creased(P<0.05),and the differences before and after treatment in the combined group were higher than those in the conventional group(P<0.05).There was no statistical significance in the total incidence rate of adverse drug reactions between the combined group(7.84%)and the conventional group(5.88%)(P>0.05).Conclusion:Budesonide combined with interferon α2 b atomization inhalation is beneficial to improve the clinical symptoms,lung function and immune inflammatory response of infants and young children with bronchopneumonia,and improve the efficacy,with high safety.

关键词

支气管肺炎/痉挛性咳嗽/布地奈德/干扰素α2b/糖皮质激素

Key words

Bronchopneumonia/Spastic cough/Budesonide/Interferon α2b/Glucocorticoid

引用本文复制引用

基金项目

2021年安徽省卫生健康委科研项目(AHWJ2021b104)

出版年

2024
河北医学
河北省医学会

河北医学

CSTPCD
影响因子:1.915
ISSN:1006-6233
段落导航相关论文